Aflibercept Intravitreous is named as an intervention in 2 current clinical trials in our China register. None are recruiting at the moment. All registered phases are Phase 4. The sponsor with the most trials is Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1). The most-studied condition is Polypoidal Choroidal Vasculopathy (PCV).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)
NCT07365371 · ClinicalTrials.gov ↗ · Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)
|
Phase 4 | Not yet open | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | China |
|
Zhuochuming®-3T&E-DME Study (Treatment-naïve Patients)
NCT07612904 · ClinicalTrials.gov ↗ · Diabetic Macular Edema (DME)
|
Phase 4 | Not yet open | The Third Peoples Hospital of Dalian | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 1 |
| The Third Peoples Hospital of Dalian | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Aflibercept Intravitreous as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) and The Third Peoples Hospital of Dalian (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Aflibercept Intravitreous works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Aflibercept Intravitreous works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Aflibercept Intravitreous (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.